Lupus Patients' shingles vaccine response under the microscope

NCT ID NCT07636044

Recruiting now Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the vaccine provides adequate protection for those with lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Shingrix (adjuvanted herpes zoster subunit vaccine)
What this could lead to: If successful, this study could show that the Shingrix vaccine works well in people with lupus, helping protect them against shingles.
What could go wrong: This is an observational study, not a treatment trial. It only measures immune response, not actual shingles prevention. Results may not apply to all lupus patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

herpes zoster systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS VACCINE REACTION ZOSTER

Contacts and locations

Locations

Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.